Analyst Research Report Snapshot

Title:

Spark Capital: 4QFY13 Result Reviews of Corporation Bank

Price:

$58.00

Provider:

Spark Capital Advisors(India) Private Limited

Date:

13 May 2013

Pages:

6

Type:

AcrobatPDF

Companies referenced:

CRBK.NS

Available for Immediate Download
Summary:

Corporation Bank 4QFY13 result review - Capital constraint compounds asset quality concerns: Maintain SELL Corporation bank’s (CRPBK) 4QFY13 performance was marked by continuing asset quality stresses, with incremental restructuring of Rs. 12.5bn taking the sheen off a 10% sequential decline in GNPAs. The overall stock of restructuring currently stands at 6.1% of the book; the restructured book has risen 2x since 2QFY12 while higher provisioning on restructured stock (Rs. 720mn) will keep provisioning elevated into FY14. Additionally, risky sector exposures have risen to 28% of the book against 25% in FY13 while exposure to power is 10% vs 8% in 1QFY12. PSL lending currently stands at 38% of ANBC and notwithstanding a 32% yoy rise in agri loans, agri continues to amount to only 9.4% of ANBC much below the mandated 18% and we expect both NIMs and asset quality to remain under pressure as these loans take-off. Opex was up 13% qoq, while pension liabilities are likely to be challenging in a wage revision year as CRPBK’s skewed rate of return on plan assets (8.85% against 8% for most PSU banks) could mean a two-fold impact on costs, a key risk in our view. CRPBK’s low T1 capital (at 8.3%) would necessitate a further infusion of capital in FY14, (in FY13 the bank only received Rs. 2bn of capital from the GOI as against a request for Rs. 10bn), ensuring the capital overhang remains; capital infusion below book value remains a key risk (refer our note “Heads I win; Tails, you lose” dated Sep 07, 2012). Compounding the problem is a dependence on hybrid T1 instruments adjusted for which T1 capital is currently at 7.6%. Even inclusive of a capital raise of Rs. 15bn therefore, the bank’s core T1 would be ~8% at end FY14, meaning frequent infusions as the transition to Basel 3 starts. With multiple headwinds continuing in the form of asset quality pressures, margins, capital and costs we maintain our SELL rating with a target price of Rs. 361, 0.8x our stress case FY14E ABV.

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.